CTU: A Phase I/II, Open-Label, Dose Escalation And Extension Study of Intravesical Eciskafusp Alfa in Combination With Bacillus Calmette-Guérin (BCG) in Participants With BCG-Unresponsive High-Risk Non- Muscle Invasive Bladder Cancer (NMIBC).

  • Zhang, Alison (Primary Chief Investigator)
  • Chapman, Nicola (Clinical Trial Unit Staff)
  • Quinlan, Gabriel (Clinical Trial Unit Staff)
  • Martin, Lewis (Clinical Trial Unit Staff)
  • Garcia, Michelle (Clinical Trial Unit Staff)
  • Armstrong, Emilia (Clinical Trial Unit Staff)

Project: Research

Project Details

Short titleBP45381
StatusFinished
Effective start/end date12/02/25 → 12/08/25